Immix Biopharma Prices Offering at $11 per Share

By Greg Peters • Thursday, October 01 01:42 • Permanent Link

Immix Biopharma priced an underwritten offering of 11,363,637 common shares at $11.00 each, putting expected gross proceeds at $125 million.

The company said the deal is expected to close on or about Sept. 30, 2026.

The new capital is earmarked for NXC-201 development, working capital and general corporate purposes.

J.P. Morgan is the sole book-running manager. The offering drew both new and existing institutional investors, including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments, Wellington Management and other biotech-focused funds.

The shares are being sold through Immix Biopharma’s shelf registration statement filed Jan. 9, 2026 and declared effective Jan. 22, 2026. Today the company's shares have moved -8.11% to a price of $10.54. For the full picture, make sure to review Immix Biopharma's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.